Biogen Idec, Inc. (Massachusetts) Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund

WESTON, Mass. & TORONTO--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and DRI Capital today announced that Biogen Idec has sold to a DRI Capital managed fund (DRI) its royalty and other rights relating to BENLYSTA® (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with Human Genome Sciences, Inc. and Glaxo Group Limited (both are companies within the GlaxoSmithKline group). BENLYSTA was approved by the US Food and Drug Administration in March 2011 and by the European Medicines Agency in July 2011 to treat systemic lupus erythematosus.